Skip to main content

01 July 2021

Are We Nearly There Yet? The Ongoing Journey of CAR T Cell Therapies

Sophie Lutter

Editorial/European Biopharmaceutical Review/01 July 2021

Download PDF – 353.8 KB

Abstract

CAR T cell therapies have been met by numerous scientific, logistical, and manufacturing challenges, and yet, a shared determination to produce readily available, cost-effective CAR T cell therapies is more present than ever.

Download the resource to continue reading.
×